肥胖对非手术性牙周治疗的影响修改
E Kaye1, R McDonough1, A Singhal2
1Department of Health Policy and Health Services Research, Boston University Henry M. Goldman School of Dental Medicine, Boston, MA, USA.
JDR clinical and translational research
|October 10, 2024
概括
肥胖会对牙周治疗的成功产生负面影响,降低成功结果的可能性. 与健康体重患者相比,肥胖患者的深口袋减肥改善较小.
科学领域:
- 牙周病学 牙周病学
- 公共卫生 公共卫生
- 肥胖问题研究研究
背景情况:
- 肥胖与更高的牙周病率有关.
- 了解身体质量指数 (BMI) 对牙周治疗的影响对于有效的患者管理至关重要.
研究的目的:
- 调查身体质量指数 (BMI) 是否会改变非手术性牙周治疗的结果.
- 为了比较肥胖,超重和健康体重患者之间的牙周治疗成功率.
主要方法:
- 在牙科学校诊所治疗的344名患有牙周病的患者进行了回顾性队列研究.
- 根据BMI分类的患者:肥胖 (≥30 kg/m2),超重 (25-29.9 kg/m2) 和健康 (18-24.9 kg/m2).
- 治疗成功被定义为缺少≥5毫米口袋;使用通用线性模型进行分析,对共变量进行调整.
主要成果:
- 肥胖与成功进行非手术性牙周治疗的可能性显著降低 (OR=0.47).
- 与健康体重患者相比,超重个体在治疗成功方面没有显著差异.
- 在治疗后的健康体重患者中,在有深口袋的部位 (PD ≥5 mm) 和临床附着性损失 (CAL ≥5 mm) 中观察到更大的减少.
结论:
- 肥胖会对非手术性牙周治疗的有效性产生不利影响.
- 研究结果表明,BMI是影响临床环境中牙周治疗结果的重要因素.
相关概念视频
Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...


